SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
NSPR reported three and nine months ended September 30, 2026 results. The price and volatility reaction is pending.
NSPRearnings

Earnings reactions, page 3

InspireMD, Inc. (NSPR) FY2026 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • Total revenue for the third quarter of 2026 was $2,242,000, compared to $2,523,000 for the third quarter of 2025.
  • International revenue for the third quarter of 2026 was $2,210,000, compared to $2,026,000 for the third quarter of 2025.
  • U.S. revenue for the third quarter of 2026 was $32,000, compared to $497,000 for the third quarter of 2025.
  • Gross profit for the third quarter of 2026 was $240,000, or 10.7% of revenue, compared to $864,000, or 34.2% of revenue, for the third quarter of 2025.
  • Net loss for the third quarter of 2026 was $9,762,000, or $0.12 per basic and diluted share, compared to a net loss of $12,708,000, or $0.17 per basic and diluted share, for the third quarter of 2025.

Notes

The U.S. sales comparison reflects the impact of the voluntary recall of the delivery system of the CGuard Prime for CAS in May 2026.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →